Latanostad Comp (Latanoprost, Timolol)

Latanoprost is a prostaglandin F2α analogue that binds to FP receptors in the ciliary body, enhancing uveoscleral outflow of aqueous humor, thereby decreasing intra‑ocular pressure. This mechanism complements timolol's effect on aqueous production.

The dosing regimen is established by the treating ophthalmologist. Typically, one drop is instilled into the affected eye(s) once daily in the evening, but the exact frequency and duration are individualized. Patients should follow the prescriber’s instructions.

Safety data for the combination in pregnancy or lactation are limited. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the prescriber should evaluate each case. Breastfeeding mothers should consult their doctor.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials. The team then provides pricing, availability, shipping details and necessary import documentation.

Compared with monotherapy agents, the latanoprost/timolol combination offers dual mechanisms—enhanced outflow and reduced production—providing greater intra‑ocular pressure reduction in a single formulation. This can improve adherence versus using separate drops, though individual response varies.

Store the eye‑drop bottles at room temperature, below 25 °C, in the original packaging. Protect from light and moisture, and keep the cap tightly closed. Do not freeze. Once opened, discard any remaining solution after the period indicated by the manufacturer.

The medication is applied topically to the eye. The patient should wash hands, tilt the head back, pull down the lower eyelid to create a pocket, and place one drop into the conjunctival sac without touching the bottle tip to the eye or lashes. Close the eye gently and avoid blinking excessively.

Although rare, serious adverse events may include severe allergic reactions, uveitis, persistent eye pain, sudden loss of vision, or systemic effects such as bradycardia and bronchospasm. Patients should seek immediate medical attention if they experience these symptoms.

Individuals with known hypersensitivity to latanoprost, timolol, prostaglandin analogues or beta‑blockers should avoid the product. It is also contraindicated in patients with active ocular infections, severe asthma, chronic obstructive pulmonary disease, or sinus bradycardia without physician supervision.